These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of juvenile spondyloarthropathies with sulfasalazine].
    Author: Job-Deslandre C, Menkès CJ.
    Journal: Rev Rhum Ed Fr; 1993; 60(7-8):489-91. PubMed ID: 7908584.
    Abstract:
    The efficacy and safety of sulfasalazine for the treatment of juvenile spondyloarthropathy were evaluated in an open study. Twenty-three patients (17 boys and 6 girls) with juvenile spondyloarthropathy inadequately controlled by nonsteroidal antiinflammatory therapy were given sulfasalazine in an average dosage of 39 mg/kg/d. After 3 months, 20 patients exhibited marked clinical improvement; of these 20, 14 discontinued or reduced their nonsteroidal antiinflammatory drug. Mean erythrocyte sedimentation rate fell significantly from 36.8 to 13.7 mm/h. After 12 months. 78% of the patients were in remission. Sulfasalazine was stopped in five patients of which none had evidence of disease relapse 6 to 12 months later. Side effects were infrequent: 2 patients had a skin rash requiring drug withdrawal and two developed mild neutropenia. These data suggest that sulfasalazine is an effective and safe second-line drug for the management of severe juvenile spondyloarthropathies.
    [Abstract] [Full Text] [Related] [New Search]